Evidence map›Paper›PMID 34495703›Full record

ArticleJournal of virology2021

Identification and Characterization of Rift Valley Fever Virus-Specific T Cells Reveals a Dependence on CD40/CD40L Interactions for Prevention of Encephalitis.

Dominique J Barbeau, Haley N Cartwright, Jessica R Harmon, Jessica R Spengler, Christina F Spiropoulou, John Sidney, Alessandro Sette, Anita K McElroy

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. In Vitro Evaluation of Bunyavirus T Cell Immunity.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Yeast Expression and Activity Assay of RVFV Polymerase.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Dominique J BarbeauUniversity of Pittsburghgrid.21925.3d School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Disease, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6493-5022
Haley N CartwrightUniversity of Pittsburghgrid.21925.3d School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Disease, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-7844-4838
Jessica R HarmonCenters for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, Georgia, USA.
Jessica R SpenglerCenters for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, Georgia, USA.ORCID 0000-0002-5383-0513
Christina F SpiropoulouCenters for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, Georgia, USA.
John SidneyCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
Anita K McElroyUniversity of Pittsburghgrid.21925.3d School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Disease, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6764-7536
Centers for Disease Control and Prevention · USUniversity of Pittsburgh · USLa Jolla Institute for Immunology · US

Funding

cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Immune correlates of protection from Rift Valley fever virusK08AI119448 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MCELROY, ANITA K · 2016 to 2019
$713k
Burroughs Wellcome Fund (BWF) 1013362.02HHS | National Institutes of Health (NIH) 75N9301900065HHS | National Institutes of Health (NIH) AI119448NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS K08 AI119448NIDA NIH HHS 75N95020D00005ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Rift Valley fever virus (RVFV) is an arbovirus found throughout Africa. It causes disease that is typically mild and self-limiting; however, some infected individuals experience severe manifestations, including hepatitis, encephalitis, or even death. Reports of RVFV encephalitis are notable among immunosuppressed individuals, suggesting a role for adaptive immunity in preventing this severe complication. This phenomenon has been modeled in C57BL/6 mice depleted of CD4 T cells prior to infection with DelNSs RVFV (RVFV containing a deletion of nonstructural protein NSs), resulting in late-onset encephalitis accompanied by high levels of viral RNA in the brain in 30% of animals. In this study, we sought to define the specific type(s) of CD4 T cells that mediate protection from RVFV encephalitis. The viral epitopes targeted by CD4 and CD8 T cells were defined in C57BL/6 mice, and tetramers for both CD4 and CD8 T cells were generated. RVFV-specific CD8 T cells were expanded and of a cytotoxic and proliferating phenotype in the liver following infection. RVFV-specific CD4 T cells were identified in the liver and spleen following infection and phenotyped as largely Th1 or Tfh subtypes. Knockout mice lacking various aspects of pathways important in Th1 and Tfh development and function were used to demonstrate that T-bet, CD40, CD40L, and major histocompatibility complex class II (MHC-II) mediated protection from RVFV encephalitis, while gamma interferon (IFN-γ) and interleukin-12 (IL-12) were dispensable. Virus-specific antibody responses correlated with protection from encephalitis in all mouse strains, suggesting that Tfh/B cell interactions modulate clinical outcome in this model.

Indexed as

CD40 AntigensCD40 LigandAfricaAnimalsAntibody FormationB-LymphocytesBrainCD8-Positive T-LymphocytesDisease Models, AnimalEncephalitis, ViralEpitopesFemaleLiverMiceMice, Inbred C57BLMice, KnockoutCD40 AntigensCD40 LigandEpitopesCD40CD40LCD4 T cellsencephalitisRift Valley fever virusRVFVTfhTh1

Identifiers

PMID34495703
PMCPMC8577384
OpenAlexW3197921559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.